As can be seen, this analysis revealed downregulation of ErbB (EGFR) and mammalian target of rapamycin (mTOR) signaling in addition to several other pathways that promote the growth and survival of glioblastoma in both cell lines following GZ17-6.02 treatment. This evidence concerns the gene EGFR and glioblastoma.